News
JNJ
160.64
+0.63%
1.00
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Seeking Alpha · 6h ago
Top 10 Dividend Stocks For A Recession-Focused Portfolio In 2024
In times of uncertainty, constructing a recession-proof portfolio can help you to reduce the volatility of your investment portfolio. I have selected 10 companies that are suitable for such a portfolio. The companies have a robust business model, strong competitive advantages, and are financially healthy. Each of the selected companies offers a sustainable dividend. PepsiCo, Visa, Apple and McDonald's are among the top 10 dividend stocks for a Recession-Focused Portfolio in 2024.
Seeking Alpha · 7h ago
Courts, Congress Likely To Stand In Way Of J&J's Third Texas Two-Step Plan; U.S. Court Of Appeals For 3rd Circuit Latest To Reject Unprecedented Bankruptcy Strategy; Lawyers On Behalf Of Ovarian Cancer Victims Are Calling On Johnson & Johnson To End Its "War Of Attrition Against Cancer Victims."
Lawyers on behalf of ovarian cancer victims call on Johnson & Johnson to end its "war of attrition against cancer victims" The company has tried to stymie lawsuits by filing for bankruptcy. A U.S. Court of appeals ruled J&J can't stash its talc liabilities in a shell subsidiary and then file for bankruptcy to avoid lawsuits.
Benzinga · 11h ago
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan
Lawyers on behalf of ovarian cancer victims are calling on Johnson & Johnson to end its “war of attrition against cancer victims.” The third time will not be the charm for J&J in its attempt to use bankruptcy to stymie thousands of lawsuits. The deadline for talc claimants to approve or reject a third bankruptcy attempt is Friday July 26.
Barchart · 16h ago
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan
Today at 5pm ET is the final deadline for tens of thousands of ovarian cancer victims to vote on the approximately $8 billion Johnson & Johnson talcum powder settlement. The plan will compensate current and future claimants who were harmed by J&J’s talc powder products. Under the plan, ovarian cancer claimants are expected to receive an average of $75,000 to $150,000 each. Talc claimants canVote on the plan at www.OfficialTalcClaims.com.
Barchart · 17h ago
J&J talc bankruptcy plan appeal denied
Seeking Alpha · 22h ago
3 Stocks Reeling From Ruined Reputations: Can They Recover?
Investorplace · 1d ago
IBM, Salesforce share gains contribute to Dow's nearly 350-point jump
MarketWatch · 1d ago
Noteworthy Thursday Option Activity: JNJ, PAYC, TGT
NASDAQ · 1d ago
AC Immune stock climbs 7% on FDA fast track status for Alzheimer's drug
AC Immune stock climbs 7% on FDA fast track status for Alzheimer's drug for the treatment of Alzheimer's disease. The drug is being developed by partner Johnson & Johnson's Janssen unit. The FDA has granted Fast Track designation to AC Immune's drug candidate.
Seeking Alpha · 1d ago
Dow's 275-point rally led by gains in IBM, Salesforce stocks
MarketWatch · 1d ago
Noteworthy ETF Outflows: IWB, JPM, JNJ, MRK
NASDAQ · 1d ago
Looking Into Johnson & Johnson's Recent Short Interest
Johnson & Johnson's short percent of float has fallen 14.77% since its last report. The company has 17.99 million shares sold short, which is 0.75% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 1d ago
AbbVie raises outlook as new immunology drugs offset Humira impact
Seeking Alpha · 1d ago
IHE: Significant Growth Ahead, But Valuation Not Cheap (Rating Downgrade)
IShares U.S. Pharmaceuticals ETF (IHE) has solid long-term growth outlook but high concentration risk. IHE's fund price has been steady with a positive trend in 2024. The fund invests in a portfolio of large-cap pharmaceutical stocks. The pharmaceuticals sector is expected to grow at a mid-single digit rate in the future. Despite its elevated valuation, IHE is a good defensive play in an economic recession.
Seeking Alpha · 1d ago
Newly-Listed Psoriasis Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Alumis Inc. Is developing oral therapies for immune-mediated diseases. The company's lead asset ESK-001 is a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus. Guggenheim Partners initiated coverage of Alumis with a Buy rating and a price target of $32.
Benzinga · 2d ago
Bio-Thera biosimilar to J&J’s Stelara under FDA review
Seeking Alpha · 2d ago
JNJ Factor-Based Stock Analysis
NASDAQ · 2d ago
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
NASDAQ · 2d ago
My Dividend Stock Portfolio: New June Dividend Record - 101 Holdings With 22 Buys
My Dividend Stock Portfolio hit a new record of 101 Holdings With 22 Buys in June. In June, Stefan Redlich added $131 to his yearly dividend income of $1.7 million. He is aiming to increase dividend income by at least $100 each month. Main portfolio picks included Ares Capital, Hercules Capital, and Goldman Sachs BDC.
Seeking Alpha · 2d ago
More
Webull provides a variety of real-time JNJ stock news. You can receive the latest news about Johnson & Johnson through multiple platforms. This information may help you make smarter investment decisions.
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).